Mereo BioPharma Group PLC ADR (MREO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mereo BioPharma Group PLC ADR (MREO) has a cash flow conversion efficiency ratio of -0.211x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.04 Million) by net assets ($28.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MREO company net worth for the company's overall valuation and market capitalisation.
Mereo BioPharma Group PLC ADR - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Mereo BioPharma Group PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mereo BioPharma Group PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mereo BioPharma Group PLC ADR ranked by their cash flow conversion efficiency. Explore MREO cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Snet systems Inc
KQ:038680
|
-0.033x |
|
Dunia Virtual Online Tbk Pt
JK:AREA
|
0.063x |
|
Hironic Co. Ltd
KQ:149980
|
0.042x |
|
Texas Community Bancshares Inc
NASDAQ:TCBS
|
0.641x |
|
Beijing North Star Company Limited
F:BJ3
|
0.078x |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
N/A |
|
TsannKuen (China) Enterprise Co. Ltd
SHE:200512
|
-0.016x |
|
Sietel Ltd
AU:SSL
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Mereo BioPharma Group PLC ADR (2015–2025)
The table below shows the annual cash flow conversion efficiency of Mereo BioPharma Group PLC ADR from 2015 to 2025. View MREO stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $40.92 Million | $-30.97 Million | -0.757x | -40.56% |
| 2024-12-31 | $60.97 Million | $-32.83 Million | -0.539x | -28.79% |
| 2023-12-31 | $50.54 Million | $-21.13 Million | -0.418x | +55.97% |
| 2022-12-31 | $51.40 Million | $-48.82 Million | -0.950x | -1498.58% |
| 2021-12-31 | $119.01 Million | $-7.07 Million | -0.059x | -103.15% |
| 2020-12-31 | $-20.47 Million | $-38.62 Million | 1.887x | +267.05% |
| 2019-12-31 | $53.33 Million | $-60.22 Million | -1.129x | -59.95% |
| 2018-12-31 | $32.77 Million | $-23.14 Million | -0.706x | -37.23% |
| 2017-12-31 | $62.48 Million | $-32.15 Million | -0.515x | -48.83% |
| 2016-12-31 | $79.26 Million | $-27.40 Million | -0.346x | -424.01% |
| 2015-12-31 | $101.54 Million | $-6.70 Million | -0.066x | -- |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more